MA45600A - Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées - Google Patents
Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associéesInfo
- Publication number
- MA45600A MA45600A MA045600A MA45600A MA45600A MA 45600 A MA45600 A MA 45600A MA 045600 A MA045600 A MA 045600A MA 45600 A MA45600 A MA 45600A MA 45600 A MA45600 A MA 45600A
- Authority
- MA
- Morocco
- Prior art keywords
- associated methods
- neuroactive steroids
- steroids substituted
- substituted
- neuroactive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
- C07J7/003—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
- C07J7/006—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360876P | 2016-07-11 | 2016-07-11 | |
| US201662360884P | 2016-07-11 | 2016-07-11 | |
| US201662360887P | 2016-07-11 | 2016-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45600A true MA45600A (fr) | 2019-05-15 |
Family
ID=59388162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045600A MA45600A (fr) | 2016-07-11 | 2017-07-11 | Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190233465A1 (fr) |
| EP (1) | EP3481844B1 (fr) |
| JP (2) | JP7065825B2 (fr) |
| AU (3) | AU2017296295B2 (fr) |
| CA (1) | CA3030420A1 (fr) |
| MA (1) | MA45600A (fr) |
| WO (1) | WO2018013615A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150291654A1 (en) | 2011-10-14 | 2015-10-15 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| JP6255082B2 (ja) | 2013-03-13 | 2017-12-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイドおよびその使用方法 |
| EP2986624B1 (fr) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs 19-nor et pour l'utilisation thérapeutique |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| EP3909966A1 (fr) | 2013-04-17 | 2021-11-17 | Sage Therapeutics, Inc. | Stéroïde 19-nor c3,3-disubstitué c21-n-pyrazolyl pour le traitement thérapeutique |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| RS61733B1 (sr) | 2013-07-19 | 2021-05-31 | Sage Therapeutics Inc | Neuroaktivni steroidi, njihove kompozicije i upotrebe |
| PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| WO2015195962A1 (fr) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, leurs compositions et utilisations |
| NZ731095A (en) | 2014-10-16 | 2023-12-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| NZ731034A (en) | 2014-10-16 | 2024-02-23 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| HUE049014T2 (hu) | 2014-11-27 | 2020-09-28 | Sage Therapeutics Inc | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére |
| JP6745274B2 (ja) | 2015-01-26 | 2020-08-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| KR20180026742A (ko) | 2015-07-06 | 2018-03-13 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| BR112018070123A2 (pt) | 2016-04-01 | 2019-02-05 | Sage Therapeutics Inc | oxiesterós e métodos de uso dos mesmos |
| WO2017193046A1 (fr) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxystérols et méthodes d'utilisation associées |
| EP3481845B1 (fr) | 2016-07-11 | 2023-09-13 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| KR20230051723A (ko) | 2016-10-18 | 2023-04-18 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| CN114805462A (zh) * | 2018-02-11 | 2022-07-29 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| CN111040015B (zh) * | 2018-10-15 | 2022-03-18 | 南京诺瑞特医药科技有限公司 | 19-去甲-c21取代类固醇衍生物 |
| WO2020135454A1 (fr) * | 2018-12-26 | 2020-07-02 | 张家口华健致远生物科技有限公司 | Classe de composés stéroïdes et leur utilisation |
| EP3911331A4 (fr) * | 2019-01-14 | 2023-01-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | Stéroïdes à substitution tétrazolone et utilisation de ces derniers |
| JOP20210293A1 (ar) | 2019-05-31 | 2023-01-30 | Sage Therapeutics Inc | ستيرويدات ذات فعالية عصبية وتركيبات منها |
| JP2022543576A (ja) * | 2019-08-07 | 2022-10-13 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ステロイド誘導体調節因子の塩及び結晶形態 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0263213B1 (fr) * | 1986-10-09 | 1995-09-06 | The Upjohn Company | Stéroides aminés en C20 à C26 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CZ301216B6 (cs) * | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
| PT2887944T (pt) | 2012-08-21 | 2022-01-10 | Sage Therapeutics Inc | Alopregnanolona para tratamento do estado de mal epiléptico refratário |
| EP3909966A1 (fr) * | 2013-04-17 | 2021-11-17 | Sage Therapeutics, Inc. | Stéroïde 19-nor c3,3-disubstitué c21-n-pyrazolyl pour le traitement thérapeutique |
| WO2015180679A1 (fr) * | 2014-05-29 | 2015-12-03 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, leurs compositions et utilisations |
| NZ731034A (en) | 2014-10-16 | 2024-02-23 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
-
2017
- 2017-07-11 JP JP2019500826A patent/JP7065825B2/ja active Active
- 2017-07-11 CA CA3030420A patent/CA3030420A1/fr active Pending
- 2017-07-11 MA MA045600A patent/MA45600A/fr unknown
- 2017-07-11 EP EP17743137.6A patent/EP3481844B1/fr active Active
- 2017-07-11 US US16/316,851 patent/US20190233465A1/en not_active Abandoned
- 2017-07-11 WO PCT/US2017/041605 patent/WO2018013615A1/fr unknown
- 2017-07-11 AU AU2017296295A patent/AU2017296295B2/en active Active
-
2021
- 2021-04-28 US US17/242,913 patent/US20230021308A9/en active Pending
-
2022
- 2022-01-14 AU AU2022200247A patent/AU2022200247B2/en active Active
- 2022-04-26 JP JP2022072338A patent/JP2022105088A/ja active Pending
-
2024
- 2024-02-09 AU AU2024200851A patent/AU2024200851A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3481844B1 (fr) | 2024-04-17 |
| CA3030420A1 (fr) | 2018-01-18 |
| JP2019520417A (ja) | 2019-07-18 |
| EP3481844A1 (fr) | 2019-05-15 |
| AU2022200247A1 (en) | 2022-02-10 |
| AU2024200851A1 (en) | 2024-02-29 |
| AU2017296295B2 (en) | 2022-02-24 |
| US20190233465A1 (en) | 2019-08-01 |
| JP2022105088A (ja) | 2022-07-12 |
| JP7065825B2 (ja) | 2022-05-12 |
| AU2022200247B2 (en) | 2024-03-07 |
| WO2018013615A1 (fr) | 2018-01-18 |
| US20220002340A1 (en) | 2022-01-06 |
| AU2017296295A1 (en) | 2019-01-24 |
| US20230021308A9 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45600A (fr) | Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| CL2018000813A1 (es) | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso. | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| CL2016002364A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas | |
| DK3142637T3 (da) | Keratin treatment formulations and methods | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| MA43385A (fr) | Nouveaux anticorps anti-claudine et méthodes d'utilisation | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| DK3149018T3 (da) | Neuroaktive steroider, sammensætninger og anvendelse deraf | |
| MA43282A (fr) | Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées | |
| DK3548135T3 (da) | Kerne-skal-mikronålsindretninger og anvendelser deraf | |
| IL285928A (en) | Fulvestrant formulations and methods of using them | |
| MA44056A (fr) | Anticorps anti-rispéridone et leur utilisation | |
| MA49905A (fr) | Polyesteramines et polyesterquats | |
| MA40512A (fr) | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants | |
| ITUA20163417A1 (it) | Fat and medical uses thereof | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| IL258429B (en) | Portable spinner and methods of use | |
| IT201700039351A1 (it) | Miscela antimeristematica e antigermogliante | |
| MA45326A (fr) | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |